164 related articles for article (PubMed ID: 34486907)
21. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
22. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
23. Sensorineural hearing loss after radiotherapy for head and neck tumors: a prospective study of the effect of radiation.
Yilmaz YF; Aytas FI; Akdogan O; Sari K; Savas ZG; Titiz A; Tumoz M; Unal A
Otol Neurotol; 2008 Jun; 29(4):461-3. PubMed ID: 18520582
[TBL] [Abstract][Full Text] [Related]
24. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
25. Risk Profiles for Sensorineural Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin-based Chemoradiation.
Shorter P; Harden F; Owen R; Panizza B; Burmeister B; Sommerville J; Mengersen K; Foote M
J Med Imaging Radiat Sci; 2017 Mar; 48(1):61-67. PubMed ID: 31047212
[TBL] [Abstract][Full Text] [Related]
26. Factors Affecting Permanent Sensorineural Hearing Loss and Bone Conduction in Patients After Receiving Radiotherapy to the Head and Neck Region.
Yücel B; Erdiş E; Bahar S; Akkaş Atasever E; Celasun MG; Altuntaş EE
Turk Arch Otorhinolaryngol; 2022 Dec; 60(4):212-219. PubMed ID: 37456600
[TBL] [Abstract][Full Text] [Related]
27. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
Niemensivu R; Saarilahti K; Ylikoski J; Aarnisalo A; Mäkitie AA
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859
[TBL] [Abstract][Full Text] [Related]
28. Audiological profile of patients treated for childhood cancer.
Liberman PH; Goffi-Gomez MV; Schultz C; Novaes PE; Lopes LF
Braz J Otorhinolaryngol; 2016; 82(6):623-629. PubMed ID: 27156673
[TBL] [Abstract][Full Text] [Related]
29. Audiological findings in patients treated with radio- and concomitant chemotherapy for head and neck tumors.
Dell'Aringa AH; Isaac ML; Arruda GV; Esteves MC; Dell'aringa AR; Júnior JL; Rodrigues AF
Radiat Oncol; 2009 Nov; 4():53. PubMed ID: 19912669
[TBL] [Abstract][Full Text] [Related]
30. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients.
Petsuksiri J; Sermsree A; Thephamongkhol K; Keskool P; Thongyai K; Chansilpa Y; Pattaranutaporn P
Radiat Oncol; 2011 Feb; 6():19. PubMed ID: 21333025
[TBL] [Abstract][Full Text] [Related]
31. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
Deutsch BC; Collopy C; Kallogjeri D; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2021 Feb; 147(2):182-189. PubMed ID: 33300954
[TBL] [Abstract][Full Text] [Related]
32. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
[TBL] [Abstract][Full Text] [Related]
33. Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study.
Musio D; DE Vincentiis M; D'Urso P; Musacchio A; Maiuri V; Zaccaro L; Ralli M; Marchetti C; Turchetta R; Tombolini V; DE Felice F
Anticancer Res; 2022 Jun; 42(6):3003-3009. PubMed ID: 35641273
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: a systematic review.
Mujica-Mota M; Waissbluth S; Daniel SJ
Head Neck; 2013 Nov; 35(11):1662-8. PubMed ID: 23280686
[TBL] [Abstract][Full Text] [Related]
35. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
36. Dosimetric parameters associated with conductive or sensorineural hearing loss 5 years after intensity-modulated radiation therapy in nasopharyngeal carcinoma.
Zhu W; Chen F; Li J; Wang W; Zhang H; Yang G; Zou L; Zhu Y; Yuan W; Ding H; Song X; Wang S
Acta Otolaryngol; 2019 Mar; 139(3):263-268. PubMed ID: 30870056
[TBL] [Abstract][Full Text] [Related]
37. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
Cohen-Cutler S; Wong K; Mena V; Sianto K; Wright MA; Olch A; Orgel E
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1488-1495. PubMed ID: 33677052
[TBL] [Abstract][Full Text] [Related]
38. Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study.
Theunissen EA; Zuur CL; Yurda ML; van der Baan S; Kornman AF; de Boer JP; Balm AJ; Rasch CR; Dreschler WA
J Otolaryngol Head Neck Surg; 2014 Aug; 43(1):30. PubMed ID: 25095702
[TBL] [Abstract][Full Text] [Related]
39. Sensorineural hearing loss following induction chemotherapy plus concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma.
Atchariyasathian V; Pruegsanusak K; Wongsriwattanakul S
J Laryngol Otol; 2015 Aug; 129(8):767-72. PubMed ID: 26112091
[TBL] [Abstract][Full Text] [Related]
40. Age-corrected hearing loss after chemoradiation in cervical cancer patients.
Marnitz S; Schermeyer L; Dommerich S; Köhler C; Olze H; Budach V; Martus P
Strahlenther Onkol; 2018 Nov; 194(11):1039-1048. PubMed ID: 30120496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
